Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

GANCICLOVIR SODIUM

All injection strengths: general benefit

Other products in the same Health Canada class (J05A, J05AB) — coverage varies; not interchangeable

  • Acyclovir (Zovirax): general benefit, Not a benefit
  • Valacyclovir (Valtrex): general benefit, Not a benefit
  • Famciclovir (Famvir): limited Use 147, Not a benefit
  • Remdesivir (Veklury): limited Use 722
  • Valganciclovir (Valcyte): limited Use 374, 568, 569, Limited Use 571, 572, 573
  • Abacavir + lamivudine + zidovudine (Trizivir): general benefit

48 more in the class list below

Cytovene · DIN 02162695 · 500mg/Vial · Pd injection-10mL Pk

General benefitMarketed · checked 2026-09-20
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Cytovene · DIN 02162695 Manufacturer: Cheplapharm Arzneimittel GmbH; listing date 2007-01-02 Health Canada: Marketed since 2019-08-09 · brand CYTOVENE · ATC J05AB06 GANCICLOVIR · form Powder for solution · route Intravenous · ingredients GANCICLOVIR (GANCICLOVIR SODIUM) 500 MG/VIAL · company Cheplapharm arzneimittel gmbh · schedule Prescription
Check this DIN again · Health Canada product record

Cytovene: Formulary list price $52.2282/unit (unit not stated in source; not the patient's cost)

Ministry pays: $52.2282 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19553 · Verify on the e-Formulary ↗ (DIN 02162695)

Source record
DIN 02162695: Cytovene Raw flags: sec3=Y Item: 081800001; group id 90; item number 0161; lccId None; manufacturer id CHE Source form: Pd Inj-10mL Pk; strength: 500mg/Vial Recorded listing: General benefit Source prices (unrounded): $52.2282; ministry $52.2282 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02162695 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19553
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (08:18 Antivirals) and how they are covered

Matched class: 08:18 Antivirals

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ABACAVIR & LAMIVUDINE & ZIDOVUDINE, ABACAVIR SULFATE, ABACAVIR SULFATE & LAMIVUDINE, BICTEGRAVIR SODIUM/EMTRICITABINE/TENOFOVIR ALAFENAMIDE HEMIFUMARATE, CABOTEGRAVIR, CABOTEGRAVIR & RILPIVIRINE, COBICISTAT & ELVITEGRAVIR & EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE, DARUNAVIR & COBICISTAT, DARUNAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE, DELAVIRDINE MESYLATE, DOLUTEGRAVIR, DOLUTEGRAVIR & ABACAVIR & LAMIVUDINE, DOLUTEGRAVIR & RILPIVIRINE, DOLUTEGRAVIR SODIUM/LAMIVUDINE, DORAVIRINE, DORAVIRINE/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ/TENOFOVIR DISOPROXIL FUMARATE/EMTRICITABINE, ELVITEGRAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE, EMTRICITABINE & RILPIVIRINE HCL & TENOFOVIR ALAFENAMIDE HEMIFUMARATE, EMTRICITABINE & RILPIVIRINE HCL & TENOFOVIR DISOPROXIL, EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE, ETRAVIRINE, FOSAMPRENAVIR CALCIUM, LAMIVUDINE & ZIDOVUDINE, LOPINAVIR & RITONAVIR, MARAVIROC, NELFINAVIR MESYLATE, RALTEGRAVIR POTASSIUM, RILPIVIRINE HYDROCHLORIDE, RITONAVIR Some products covered without a code (check the product listing): ACYCLOVIR, ATAZANAVIR SULFATE, DARUNAVIR, EFAVIRENZ, LAMIVUDINE, NEVIRAPINE, VALACYCLOVIR 08:18 Antivirals

ACYCLOVIR

· 15 products · Listed, not a benefit (2), General benefit (13) · strengths: 200mg, 400mg, 800mg · Tab

VALACYCLOVIR

· 21 products · General benefit (13), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 500mg, 1000mg · Tab

FAMCICLOVIR

· 6 products · Off-Formulary Interchangeable, not an ODB benefit (4), Limited Use, codes 147 (2) · strengths: 125mg, 250mg, 500mg · Tab

REMDESIVIR

· 1 products · Limited Use, codes 722 · strengths: 100mg/vial · Pd for Sol-100mg Vial Pk

VALGANCICLOVIR

· 6 products · Limited Use, codes 571, 572, 573 (2), Limited Use, codes 374, 568, 569 (4) · strengths: 50mg/mL, 450mg · Pd for Oral Sol-100mL Pk, Tab

ABACAVIR & LAMIVUDINE & ZIDOVUDINE

· 2 products · General benefit · strengths: 300mg & 150mg & 300mg · Tab

ABACAVIR SULFATE

· 4 products · General benefit · strengths: 20mg/mL, 300mg · O/L, Tab

ABACAVIR SULFATE & LAMIVUDINE

· 7 products · General benefit · strengths: 600mg & 300mg · Tab

ATAZANAVIR SULFATE

· 12 products · General benefit (8), Off-Formulary Interchangeable, not an ODB benefit (4) · strengths: 150mg, 200mg, 300mg · Cap

BICTEGRAVIR SODIUM/EMTRICITABINE/TENOFOVIR ALAFENAMIDE HEMIFUMARATE

· 1 products · General benefit · strengths: 50mg & 200mg & 25mg · Tab

CABOTEGRAVIR

· 3 products · General benefit · strengths: 200mg/mL, 30mg · Inj Sol-ER Susp 3mL Vial Kit Pk, Tab

CABOTEGRAVIR & RILPIVIRINE

· 2 products · General benefit · strengths: 200mg/mL & 300mg/mL · Inj Sol-2mL Kit, Inj Sol-3mL Kit Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:18 and 42 more
Full class listing Related classes: 08:08 Anthelmintics, 08:12 Antibiotics, 08:14 Antifungals, 08:16 Antitubercular Agents, 08:20 Plasmodicides (Antimalarials), 08:24 Sulfonamides, 08:30 Antiprotozoals, 08:32 Trichomonacides, 08:36 Urinary Anti-Infectives, 08:40 Miscellaneous Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE CYTOVENE (ganciclovir for injection) is indicated for the treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients, including patients with acquired immunodeficiency syndrome (AIDS), iatrogenic suppression secondary to organ transplantation or those administered chemotherapy for neoplasia. CYTOVENE is also indicated for the prevention of CMV disease in transplant recipients at risk for CMV disease. The diagnosis of CMV retinitis is primarily an ophthalmologic one and should be made by indirect ophthalmoscopy. Other conditions in the differential diagnosis of CMV retinitis include candidiasis, toxoplasmosis, histoplasmosis, retinal scars, and cotton wool spots, any of which may produce a retinal appearance similar to CMV. For this reason it is essential that the diagnosis of CMV be established by an ophthalmologist familiar with the retinal presentation of these conditions. The diagnosis of CMV retinitis may be aided by culture of CMV from urine, blood, throat, or other sites, but a negative CMV culture does not rule out CMV retinitis. Geriatrics(≥65 years of age) : No studies on the efficacy or safety of CYTOVENE specifically in elderl… https://pdf.hres.ca/dpd_pm/00046514.PDF PM date: July 20, 2018 Source product: CYTOVENE; DIN 02162695; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.